Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
19
|
pubmed:dateCreated |
1990-12-21
|
pubmed:abstractText |
The aim of the study was to investigate the influence of 40 mg of the beta-blocker penbutolol (Betapressin TM; Hoechst Ltd., Frankfurt/Main) in comparison to placebo on the insulin consumption on the blood sugar profile in twelve insulin-dependent diabetes (IDDM) patients. The patients were treated with penbutolol and placebo for a period of three days, and then were examined with the help of the glucose-controlled insulin infusion system. The blood sugar profile and insulin consumption over a 24 hour period was not affected by either penbutolol or placebo, nor could any changes be measured in these parameters when measured after food intake. After a submaximal exercise load on the bicycle ergometer (1 watt per kg body weight) following an evening meal, no difference could be observed between penbutolol and placebo in the above-mentioned parameters. The same was also true for hormonal parameters as STH, ACTH, cortisol, and catecholamines. These findings demonstrated that medication of penbutolol over a three-day period has no influence on the baseline blood sugar profile and insulin consumption or on insulin consumption after food intake during rest and physical exercise.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Catecholamines,
http://linkedlifedata.com/resource/pubmed/chemical/Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Penbutolol,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0023-2173
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
3
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
951-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2232625-Adolescent,
pubmed-meshheading:2232625-Adult,
pubmed-meshheading:2232625-Blood Glucose,
pubmed-meshheading:2232625-Catecholamines,
pubmed-meshheading:2232625-Diabetes Mellitus, Type 1,
pubmed-meshheading:2232625-Exercise,
pubmed-meshheading:2232625-Female,
pubmed-meshheading:2232625-Hormones,
pubmed-meshheading:2232625-Humans,
pubmed-meshheading:2232625-Insulin,
pubmed-meshheading:2232625-Insulin Infusion Systems,
pubmed-meshheading:2232625-Male,
pubmed-meshheading:2232625-Penbutolol,
pubmed-meshheading:2232625-Placebos
|
pubmed:year |
1990
|
pubmed:articleTitle |
The influence of penbutolol and placebo on blood sugar levels and insulin consumption in the glucose-controlled insulin infusion system ("artificial endocrine pancreas").
|
pubmed:affiliation |
III. Medizinische Klinik und Poliklinik, Innere Medizin und Endokrinologie, Johannes Gutenberg-Universität Mainz.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Controlled Clinical Trial
|